BASEL (AFX) - Roche Holding AG said an interim analysis of a Phase III study of Avastin in advanced renal cell cancer has shown that the drug significantly prolongs progression-free survival.
Due to the benefits observed, the independent Drug Safety Monitoring Board has recommended that the study be unblinded and all patients will be offered treatment with Avastin.
In addition, this early analysis indicated a trend towards an improvement in overall survival.
Renal cell cancer is the most common form of kidney cancer accounting for nine out of ten cases and treatment options are limited.
Safety was in line with what has been observed for Avastin in previous studies.
source - AFX